Kainos Medicine, Inc. (KOSDAQ:284620)
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 4,222 | 3,834 | 16,337 | 24,952 | 23,231 | 21,952 |
Short-Term Investments | - | - | 79.85 | 5,000 | 11,000 | 6,000 |
Trading Asset Securities | - | - | - | - | - | 1,860 |
Cash & Short-Term Investments | 4,222 | 3,834 | 16,417 | 29,952 | 34,231 | 29,812 |
Cash Growth | -48.35% | -76.64% | -45.19% | -12.50% | 14.82% | 682.29% |
Accounts Receivable | 278.11 | 252.77 | 83.75 | -0 | 0 | -0 |
Other Receivables | 71.19 | 62.53 | 4.35 | 295.7 | 290.89 | 59.02 |
Receivables | 349.29 | 490.3 | 88.1 | 295.7 | 290.89 | 59.02 |
Prepaid Expenses | 74.88 | 96.69 | 258.68 | 949.3 | 2,020 | 197.25 |
Other Current Assets | 317.01 | 182.94 | 353.43 | 38.45 | 331.12 | 1,918 |
Total Current Assets | 5,645 | 4,604 | 17,117 | 31,236 | 36,873 | 31,987 |
Property, Plant & Equipment | 285.08 | 602.75 | 875.47 | 5,437 | 3,334 | 1,851 |
Long-Term Investments | 1,940 | 3,503 | 786.56 | 740.63 | 642.79 | - |
Other Intangible Assets | 442.41 | 501.61 | 810.67 | 861.84 | 689.04 | 481.59 |
Long-Term Accounts Receivable | 0 | -0 | 0 | -0 | -0 | 0 |
Other Long-Term Assets | 1,439 | 1,531 | 1,395 | 707.04 | 418.79 | 458.9 |
Total Assets | 9,751 | 10,742 | 20,985 | 38,982 | 41,957 | 34,779 |
Accrued Expenses | 124.54 | 99.83 | 49.92 | 65.04 | 575.51 | 197.4 |
Short-Term Debt | - | - | - | 761.67 | 12,468 | - |
Current Portion of Long-Term Debt | - | - | - | 2,285 | - | - |
Current Portion of Leases | 225.96 | 355.37 | 352.17 | 550.74 | 276.27 | 269.75 |
Other Current Liabilities | 1,531 | 1,931 | 1,400 | 1,213 | 8,779 | 436.18 |
Total Current Liabilities | 1,881 | 2,386 | 1,802 | 4,876 | 22,099 | 903.33 |
Long-Term Debt | - | - | - | - | 1,523 | 10,739 |
Long-Term Leases | - | 135.91 | 48.66 | 314.34 | 103.95 | 284.97 |
Other Long-Term Liabilities | 35.15 | 33.75 | 36.62 | 73.8 | 73.92 | 6,567 |
Total Liabilities | 1,916 | 2,556 | 1,888 | 5,264 | 23,800 | 18,494 |
Common Stock | 16,543 | 14,090 | 13,961 | 13,961 | 11,029 | 10,494 |
Additional Paid-In Capital | 116,022 | 111,617 | 110,117 | 110,117 | 84,564 | 71,602 |
Retained Earnings | -134,533 | -128,605 | -116,414 | -101,179 | -85,298 | -69,087 |
Treasury Stock | -40.95 | -40.95 | -55.12 | -55.12 | -22.72 | -22.72 |
Comprehensive Income & Other | 4,182 | 4,726 | 4,143 | 3,266 | 1,831 | -634.39 |
Total Common Equity | 2,173 | 1,788 | 11,751 | 26,109 | 12,104 | 12,353 |
Minority Interest | 3,456 | 4,086 | 4,020 | 3,808 | 2,497 | 667.81 |
Shareholders' Equity | 7,835 | 8,186 | 19,098 | 33,719 | 18,157 | 16,284 |
Total Liabilities & Equity | 9,751 | 10,742 | 20,985 | 38,982 | 41,957 | 34,779 |
Total Debt | 225.96 | 491.29 | 400.83 | 3,912 | 14,372 | 11,294 |
Net Cash (Debt) | 3,996 | 3,343 | 16,016 | 26,040 | 19,859 | 18,519 |
Net Cash Growth | -47.73% | -79.13% | -38.50% | 31.12% | 7.24% | 413.89% |
Net Cash Per Share | 131.45 | 120.05 | 573.59 | 1092.41 | 937.14 | 913.99 |
Filing Date Shares Outstanding | 32.71 | 27.81 | 27.92 | 27.92 | 22.06 | 20.99 |
Total Common Shares Outstanding | 32.71 | 27.81 | 27.92 | 27.92 | 22.06 | 20.99 |
Working Capital | 3,764 | 2,218 | 15,315 | 26,360 | 14,774 | 31,083 |
Book Value Per Share | 66.44 | 64.30 | 420.94 | 935.25 | 548.77 | 588.61 |
Tangible Book Value | 1,731 | 1,286 | 10,941 | 25,247 | 11,414 | 11,871 |
Tangible Book Value Per Share | 52.92 | 46.26 | 391.90 | 904.38 | 517.53 | 565.66 |
Machinery | 739.46 | 743.51 | 760.19 | 749.6 | 725.66 | 1,061 |
Construction In Progress | - | - | - | 3,829 | 2,287 | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.